Elanco's pricing held firm in Q3 while rivals discounted, a choice that tests whether proprietary products can continue to win share without cutting prices.
ELAN Elanco Animal Health Incorporated Common Stock
XNYS
27.02
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ELAN
$27.02
—
What changed
Recent filings, trades and movesKey stats
$27.02
- 52-Week Range
- $19.40 – $27.98
- YTD
- +19.99%
- IV Rank (30D)
- 0.0
- Straddle Price
- $2.70
- P/C Vol Ratio
- 0.86
- Market Cap
- $12.9B
- Open
- $26.19
- Day Range
- $26.00 – $27.08
- Volume
- 4,222,664
- Prev Close
- $25.74
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.04 |
| Cost of Equity (CAPM) | 10.24% (VRP-adj) |
| WACC | 9.36% |
| Volatility Risk Premium | +5.4pp (IV − HV30), ERP adj +12bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +20.3% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.4B |
| Return on Equity (TTM) | -3.0% |
| Book / Price | 50.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 55.4% |
| FCF Margin (TTM) | 7.5% |
| Debt / Equity | 0.58 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +20.9% (reverse-DCF on current price) |
| SMA 50 | $23.13 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $23.33 |
| Bollinger Width / SMA20 | 16.0% (drives anchor stability) |
| Net Debt | $3.3B |
| Market Cap | $13B |
Peers used for multiples: JAZZ, PFE, VTRS
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
18%
20-Day Fair Value
≈ by Dec 8, 2026
$27.27
α +0.7%
rank 14%
conviction
52%
40-Day Fair Value
≈ by Jan 6, 2027
$27.39
α +1.2%
rank 12%
conviction
42%
60-Day Fair Value
≈ by Feb 4, 2027
$27.24
α +0.6%
rank 17%
conviction
18%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $24.64 | 24% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | $15.69 | 7% | median 10.0× · 3 peers |
| Peer P/B | $24.87 | 10% | median 1.9× · 3 peers |
| Peer P/S | $29.25 | 10% | median 2.7× · 3 peers |
| Market Anchor (SMA50) | $23.13 | 34% | stability 70% (BB-width) |
| Options Expected (B-L 30d) | $26.08 | 15% | 12 strikes · skew +0.03 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $12.9B
- Employees
- 9,900
- List Date
- 2018-09-20
- CIK
- 0001739104
- Last Earnings
- Nov 6 before open · +8.7% vs ±11.1% expected
- Next Earnings
- ~Feb 23, 2027 (estimated)
- Headquarters
- Indianapolis, IN
- Homepage
- https://www.elanco.com
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -4.82% | -7.82% | 11.17% | 0.68% | -0.17% | 6.93% | 0.99% |
| Feb | 10.23% | 11.24% | -18.42% | 7.44% | -4.69% | 6.67% | 2.08% |
| Mar | -12.48% | -9.85% | -16.52% | 1.56% | -7.16% | -8.28% | -8.79% |
| Apr | 10.14% | -3.10% | 2.38% | -17.60% | -8.41% | -3.24% | -3.31% |
| May | 13.14% | -5.77% | -15.10% | 34.45% | 41.92% | 5.95% | 12.43% |
| Jun | -2.28% | -18.65% | 16.98% | -18.66% | 6.41% | 3.97% | -2.04% |
| Jul | 4.20% | -1.75% | 20.34% | -7.52% | -5.20% | 8.81% | 3.15% |
| Aug | -8.55% | -22.88% | 1.92% | 18.63% | 33.07% | -7.00% | 2.53% |
| Sep | -4.89% | -19.31% | -9.28% | -2.97% | 12.83% | -6.36% | -5.00% |
| Oct | 2.46% | 5.02% | -19.62% | -12.83% | 6.49% | 5.93% | -2.09% |
| Nov | -12.56% | -3.09% | 36.50% | 4.84% | 1.84% | 12.28%* | 6.64% |
| Dec | 0.85% | -7.35% | 20.16% | -10.16% | 0.04% | -- | 0.71% |
| Total | -8.44% | -60.41% | 12.93% | -13.48% | 88.68% | 25.67% | 7.49% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $23.55
SMA 50: $23.19
SMA 200: $23.81
Current: $27.05
EMA 12: $24.42
EMA 26: $23.72
MACD: 0.6931 | Signal: 0.3898
BULLISH
ADX (14): 18.02
RANGE
+DI: 34.01
−DI: 15.50
Momentum Oscillators
RSI (14): 70.25
OVERBOUGHT
Stoch %K: 78.39
Stoch %D: 78.00
Williams %R: -0.71
Volume & Volatility
BB Upper: $25.98
BB Lower: $21.12
OVERBOUGHT
OBV: -8,207,437
Vol SMA 20: 5,423,197
Vol ROC: -1.88%
ATR: $0.97
True Range: $1.34
HV 20: 51.4%
HV 30: 44.2%
HV 60: 37.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before ELAN’s Nov 6 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Positive news sentiment driven by recent headlines
- Bullish momentum signals from MACD and RSI
- Higher beta relative to the market indicates increased volatility
Primary Risks:
- High risk due to high volatility and strong positive news sentiment
- Risk of pullback or consolidation if price reaches upper Bollinger Band
Investment Thesis:
ELAN is likely to continue its upward trend driven by positive news sentiment, bullish momentum signals, and higher beta. However, investors should be cautious of potential risks and consider position sizing accordingly.
Recent News Sentiment Impact:
The recent headlines have been overwhelmingly positive, contributing to the strong bullish momentum in ELAN's stock price. The market narrative suggests that Elanco Animal Health is well-positioned for growth, with investments and product momentum driving the company forward.
Technical Analysis
Trend Direction:
- Short-term: Bullish (4 weeks)
- Medium-term: Bullish (3 months)
- Long-term: Neutral (12 months)
Support/Resistance Levels:
- Lower Bollinger Band: $23.55
- Middle Line: $25.38
- Upper Bollinger Band: $27.21
Momentum Signals:
- RSI: 32.19 (neutral) - indicates potential for further upside
- MACD: Bullish momentum signal with a histogram reading of 0.31
- Bollinger Bands: Oversold, indicating potential for a bounce
Volume Analysis:
- Volume SMA 20: 6269070.70
- On-Balance Volume (OBV): 18269578.01
- Volume Rate of Change: 451.25% - indicates increased buying pressure
News & Sentiment Analysis
Recent Headlines Summary:
The recent headlines have been overwhelmingly positive, highlighting Elanco Animal Health's growth potential and product momentum.
Sentiment Assessment:
Aggregate news sentiment is POSITIVE, contributing to the strong bullish momentum in ELAN's stock price.
Catalyst Identification:
- Upcoming earnings release (no date available)
- Potential for continued product momentum and investment growth
Market Narrative:
The market narrative suggests that Elanco Animal Health is well-positioned for growth, with investments and product momentum driving the company forward. This positive news sentiment has contributed to the strong bullish momentum in ELAN's stock price.
Risk & Volatility Assessment
Beta Interpretation:
- Beta: 1.37 (vs SPY) - indicates higher risk relative to the market
Volatility Regime:
- Current volatility is high, indicating increased risk
- Historical volatility is moderate to high
Options Market Signals:
- IV Rank: Low (9.0%)
- Put/Call Volume Ratio: Neutral sentiment (0.90)
- Options market pricing a $2.78 move by expiration - indicates potential for further upside
Downside Protection:
- Support levels: Lower Bollinger Band ($23.55), Middle Line ($25.38)
- Risk management considerations: Position sizing, stop-loss levels, and profit-taking strategies
Market Context & Positioning
Sector Performance:
ELAN is outperforming the broader market, with a relative strength indicator reading of 0.42.
Institutional Activity:
Volume patterns suggest increased institutional interest in ELAN, with an On-Balance Volume (OBV) reading of 18269578.01.
Correlation Analysis:
ELAN's stock price is highly correlated with the overall market, with an R-squared value of 0.80.
Relative Valuation:
ELAN is trading within a relatively tight range, with a relative strength indicator reading of 0.42. This suggests that the stock may be due for a pullback or consolidation.
Key Levels & Action Items
Critical Price Levels:
- Support levels: Lower Bollinger Band ($23.55), Middle Line ($25.38)
- Resistance levels: Upper Bollinger Band ($27.21)
Breakout/Breakdown Levels:
- Potential breakout above the upper Bollinger Band
- Potential breakdown below the lower Bollinger Band
Time-Sensitive Catalysts:
- Upcoming earnings release (no date available)
- Potential for continued product momentum and investment growth
Risk Management:
- Position sizing: Consider reducing exposure if price reaches upper Bollinger Band or increasing exposure if price pulls back to Middle Line
- Stop-loss levels: Set stop-loss at $23.55 (Lower Bollinger Band) or $24.67 (SMA 50)
- Profit-taking strategies: Consider taking profits if price reaches the upper Bollinger Band or above
Generated
News
All ELAN news →
Elanco Animal Health shares rose nearly 8% after the company reported third-quarter earnings above expectations and raised its full-year outlook. Jeff Simmons, Elanco’s President and CEO, called it a high-quality quarter, citing 11% reported growth and broad strength across…
Elanco beat expectations and raised guidance on strong innovation sales.
Earnings History
16 of 24 under expected move
Avg Expected Move
10.35%
Avg Actual Move
8.38%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-24 | Pre-Market | 10.37% | 2.24% | 0.22x | Within |
| 2021-05-07 | Pre-Market | 7.05% | 5.89% | 0.84x | Within |
| 2021-08-09 | Pre-Market | 6.25% | 16.09% | 2.57x | Exceeded |
| 2021-11-05 | Pre-Market | 7.67% | 3.71% | 0.48x | Within |
| 2022-01-10 | Pre-Market | 4.07% | 6.21% | 1.53x | Exceeded |
| 2022-02-24 | Pre-Market | 9.71% | 8.31% | 0.86x | Within |
| 2022-05-09 | Pre-Market | 8.87% | 8.20% | 0.92x | Within |
| 2022-08-08 | Pre-Market | 9.83% | 2.42% | 0.25x | Within |
| 2022-11-08 | Pre-Market | 11.00% | 2.23% | 0.20x | Within |
| 2023-05-09 | Pre-Market | 13.14% | 0.53% | 0.04x | Within |
| 2023-08-07 | Pre-Market | 11.85% | 4.03% | 0.34x | Within |
| 2023-11-07 | Pre-Market | 11.22% | 14.32% | 1.28x | Exceeded |
| 2024-02-26 | Pre-Market | 10.26% | 0.67% | 0.07x | Within |
| 2024-05-08 | Pre-Market | 10.43% | 24.93% | 2.39x | Exceeded |
| 2024-08-08 | Pre-Market | 14.74% | 4.93% | 0.33x | Within |
| 2024-11-07 | Pre-Market | 8.94% | 12.75% | 1.43x | Exceeded |
| 2025-02-25 | Pre-Market | 12.83% | 3.69% | 0.29x | Within |
| 2025-05-07 | Pre-Market | 6.57% | 26.29% | 4.00x | Exceeded |
| 2025-08-07 | Pre-Market | 11.11% | 18.14% | 1.63x | Exceeded |
| 2025-11-05 | Pre-Market | 14.44% | 4.00% | 0.28x | Within |
| 2026-02-24 | Pre-Market | 12.22% | 6.59% | 0.54x | Within |
| 2026-05-06 | Pre-Market | 11.09% | 13.88% | 1.25x | Exceeded |
| 2026-08-05 | Pre-Market | 13.57% | 2.42% | 0.18x | Within |
| 2026-11-06 | Pre-Market | 11.09% | 8.70% | 0.78x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ELAN Options Activity & IV Rank
ELAN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 38.6%
7-DTE IV: 39.4%
Expected Move: $2.70
7-DTE Move: $1.48
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,710
Put Volume: 1,469
P/C Volume: 0.859
NEUTRAL
Call OI: 8,001
Put OI: 8,674
P/C OI: 1.084
Total OI: 16,675
ATM Options Pricing
ATM Call: $1.30
ATM Put: $1.40
Call %: 4.8%
Put %: 5.2%
Chain Summary
Chain Volume: 3,179
Chain OI: 16,675
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 50th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
50%
vs own history
GEX tilt
+0.19
OI-weighted, today
Vanna tilt
+0.30
δ-sensitivity to IV
Charm tilt
-0.74
δ-decay vs time
Charm tilt -0.74: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 28 ATM contracts, 7k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)4.1LowNov 9
IV Rank (30 DTE)0.0LowNov 9
Straddle Price (30 DTE)$2.70Nov 9
Beta Analysis
Risk Metrics
Beta: 1.3414
Alpha: 15.93%
Correlation: 0.4219
R-Squared: 17.8%
Stock Volatility: 43.7%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ELAN
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $237.9M | #150 of 6285 | +120.4% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $67.1M | #485 of 3716 | +281.8% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $2.0M | #710 of 997 | -3.8% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $638K | #1957 of 4729 | -60.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ELAN Institutional Ownership (13F)
Filings for 2026-06-30 · 244 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 501,275,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
9 filers$11.64M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.60M | 22.37% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $2.41M | 20.70% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $2.30M | 19.76% | 2026-09-30 |
| 4 | Jane Street Group, LLC Custodian | $1.13M | 9.73% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $994.12K | 8.54% | 2026-09-30 |
| 6 | Walleye Capital LLC | $890.88K | 7.65% | 2026-06-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $839.20K | 7.21% | 2026-06-30 |
| 8 | Caption Management, LLC | $462.67K | 3.98% | 2026-06-30 |
| 9 | Walleye Trading LLC | $7.38K | 0.06% | 2026-06-30 |
7 filers$6.03M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.80M | 29.85% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $1.32M | 21.90% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $794.85K | 13.17% | 2026-09-30 |
| 4 | Walleye Capital LLC | $735.84K | 12.19% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $615.25K | 10.20% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $442.98K | 7.34% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $322.42K | 5.34% | 2026-09-30 |
ELAN Insider Trading (Form 4)
Latest: 2026-11-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | Rajeev A. Modi | SEE REMARKS | Grant (A) | +64 RSU | — | EDGAR | |
| 2026-11-03 | Jeffrey N Simmons | PRESIDENT, CEO AND DIRECTOR | Grant (A) | +122 RSU | — | EDGAR | |
| 2026-11-03 | Robert M VanHimbergen | EVP and CFO | Grant (A) | +8 RSU | — | EDGAR | |
| 2026-10-20 | Rajeev A. Modi | SEE REMARKS | Grant (A) | +62 RSU | — | EDGAR | |
| 2026-10-20 | Robert M VanHimbergen | EVP and CFO | Grant (A) | +8 RSU | — | EDGAR | |
| 2026-10-20 | Jeffrey N Simmons | PRESIDENT, CEO AND DIRECTOR | Grant (A) | +120 RSU | — | EDGAR | |
| 2026-10-19 | Timothy J Bettington | SEE REMARKS | Sell (S) | −4,350 | $23.00 | -$100.0K | EDGAR |
| 2026-10-06 | Robert M VanHimbergen | EVP and CFO | Grant (A) | +8 RSU | — | EDGAR | |
| 2026-10-06 | Rajeev A. Modi | SEE REMARKS | Grant (A) | +66 RSU | — | EDGAR | |
| 2026-10-06 | Jeffrey N Simmons | PRESIDENT, CEO AND DIRECTOR | Grant (A) | +127 RSU | — | EDGAR | |
| 2026-10-01 | Kapila K Anand | Director | Grant (A) | +642 RSU | — | EDGAR | |
| 2026-09-22 | Robert M VanHimbergen | EVP and CFO | Grant (A) | +8 RSU | — | EDGAR | |
| 2026-09-22 | Jeffrey N Simmons | PRESIDENT, CEO AND DIRECTOR | Grant (A) | +126 RSU | — | EDGAR | |
| 2026-09-22 | Rajeev A. Modi | SEE REMARKS | Grant (A) | +65 RSU | — | EDGAR | |
| 2026-09-09 | Jeffrey N Simmons | PRESIDENT, CEO AND DIRECTOR | Grant (A) | +115 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ELAN Insider Holdings
26 insiders · @ $27.05
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jeffrey N Simmons | PRESIDENT, CEO AND DIRECTOR | 2,223,869 | $60.14M | $4.56M | 94 | 2026-11-03 |
| 2 | Ramiro Martin Cabral | SEE REMARKS | 283,874 | $7.68M | $24.0K | 15 | 2026-03-05 |
| 3 | Ellen de Brabander | SEE REMARKS | 280,821 | $7.59M | $0 | 10 | 2026-04-07 |
| 4 | David S Kinard | SEE REMARKS | 214,264 | $5.79M | $60.0K | 16 | 2026-07-02 |
| 5 | Todd S. Young | SEE REMARKS | 206,469 | $5.58M | $265.7K | 13 | 2025-03-05 |
| 6 | Lawrence Erik Kurzius | Director | 188,647 | $5.10M | $1.60M | 19 | 2026-08-21 |
| 7 | Rajeev A. Modi | SEE REMARKS | 160,812 | $4.35M | $195.9K | 83 | 2026-11-03 |
| 8 | Timothy J Bettington | SEE REMARKS | 138,911 | $3.76M | -$100.0K | 9 | 2026-10-19 |
| 9 | Robert M VanHimbergen | EVP and CFO | 137,516 | $3.72M | $247.4K | 25 | 2026-11-03 |
| 10 | Michael J Harrington | Director | 131,451 | $3.56M | $305.2K | 10 | 2026-08-13 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ELAN Board & Officers
As of SEC filings through Nov 3, 2026Directors 11
- Jeffrey N Simmons · since Sep 19, 2018
- Kapila K Anand · since Sep 19, 2018
- Lawrence Erik Kurzius · since Sep 19, 2018
- Michael J Harrington · since Sep 19, 2018
- R David Hoover · since Sep 19, 2018
- Deborah Turner Kochevar · since Mar 11, 2019
- Denise Scots-Knight · since Mar 11, 2019
- Kirk P McDonald · since Mar 11, 2019
- Art A Garcia · since May 8, 2019
- Paul Herendeen · since Dec 14, 2020
- Stacey Ma · since Nov 11, 2024
Officers 12
- Jeffrey N Simmons · President, CEO and Director · listed since Feb 2020
- de Simas Jose Manuel Correia · Executive Vice President, US Farm Animal Business · since Apr 20, 2020
- David S Kinard · Executive Vice President, Human Resources, Corporate Affairs and Administration · listed since Jan 2021
- Ramiro Martin Cabral · Executive Vice President - Elanco International · listed since Jan 2021
- Rajeev A. Modi · Executive Vice President U.S. Pet Health and Global Digital Transformation · since Mar 24, 2022
- Ellen de Brabander · Executive Vice President, Research, Development and Regulatory Affairs · listed since Mar 2026
- Timothy J Bettington · Executive Vice President, Center of Strategic Growth · listed since Mar 2026
- Robert M VanHimbergen · EVP and CFO · since Jul 7, 2025
- James M Meer · Chief Accounting Officer · since Sep 24, 2018
- Jamie Preston · EVP, Chief People Officer · since Nov 3, 2026
- Grace McArdle · EVP, Manufacturing and Quality · since Jul 1, 2023
- Shiv O'Neill · GC and Corp Sec · listed since Mar 2024
Changes in the last 10 years (65)
| Nov 3, 2026 | Jamie Preston became EVP, Chief People Officer |
| Mar 3, 2026 | Timothy J Bettington listed as Executive Vice President, Center of Strategic Growth (previously Executive Vice President, Corporate Strategy and Market Development) in SEC filings |
| Mar 3, 2026 | Ellen de Brabander listed as Executive Vice President, Research, Development and Regulatory Affairs (previously Executive Vice President of Innovation and Regulatory Affairs) in SEC filings |
| Jul 7, 2025 | Robert M VanHimbergen became EVP and CFO |
| Nov 11, 2024 | Stacey Ma became a director |
| Mar 29, 2024 | Kathy V Turner became a director |
| Mar 29, 2024 | Craig S. Wallace became a director |
| Mar 5, 2024 | Shiv O'Neill listed as GC and Corp Sec (previously Interim GC and Corp Sec) in SEC filings |
| Nov 17, 2023 | Shiv O'Neill became Interim GC and Corp Sec |
| Jul 1, 2023 | Grace McArdle became EVP, Manufacturing and Quality |
| Mar 20, 2023 | Timothy J Bettington became Executive Vice President, Corporate Strategy and Market Development |
| Mar 24, 2022 | Rajeev A. Modi became Executive Vice President U.S. Pet Health and Global Digital Transformation |
| Oct 18, 2021 | Ellen de Brabander became Executive Vice President of Innovation and Regulatory Affairs |
| Oct 5, 2021 | The company announced the departure of Aaron L Schacht as Executive Vice President, Innovation, Regulatory and Business Development in an SEC filing |
| Jul 2, 2021 | Marcela A. Kirberger listed as Executive Vice President, General Counsel and Corporate Secretary (previously Ex VP, Gen Counsel & Corp Sec) in SEC filings |
| Jun 22, 2021 | Marcela A. Kirberger became Ex VP, Gen Counsel & Corp Sec |
| Jan 5, 2021 | Ramiro Martin Cabral listed as Executive Vice President - Elanco International (previously Executive Vice Presideent, Elanco International) in SEC filings |
| Jan 5, 2021 | David S Kinard listed as Executive Vice President, Human Resources, Corporate Affairs and Administration (previously Executive Vice President, Human Resources) in SEC filings |
| Dec 14, 2020 | William F Doyle became a director |
| Dec 14, 2020 | Paul Herendeen became a director |
| Dec 13, 2020 | Uncas GP LLC became a director |
| Dec 13, 2020 | Scott D. Ferguson became a director |
| Dec 13, 2020 | Sachem Head GP LLC became a director |
| Dec 13, 2020 | Sachem Head Capital Management LP became a director |
| Dec 3, 2020 | Bayer World Investments B.V. reported in an SEC filing no longer being a 10% owner |
| Dec 3, 2020 | Aktiengesellschaft Bayer reported in an SEC filing no longer being a 10% owner |
| Aug 1, 2020 | Joyce J. Lee became Ex VP Prs US Pet Hlth Com Op |
| Aug 1, 2020 | Dirk Ehle became Ex VP & Pres Elanco Europe |
| Aug 1, 2020 | Bayer World Investments B.V. became a 10% owner |
| Aug 1, 2020 | Aktiengesellschaft Bayer became a 10% owner |
| Apr 20, 2020 | de Simas Jose Manuel Correia became Executive Vice President, US Farm Animal Business |
| Apr 20, 2020 | Racquel Harris Mason became Executive Vice President and Chief Marketing Officer |
| Feb 4, 2020 | Jeffrey N Simmons listed as President, CEO and Director (previously Presiident, CEO & Director) in SEC filings |
| May 8, 2019 | Art A Garcia became a director |
| Mar 11, 2019 | LILLY ELI & CO reported in an SEC filing no longer being a 10% owner |
| Mar 11, 2019 | Kirk P McDonald became a director |
| Mar 11, 2019 | John P Bilbrey became a director |
| Mar 11, 2019 | Denise Scots-Knight became a director |
| Mar 11, 2019 | Deborah Turner Kochevar became a director |
| Mar 5, 2019 | Sarena S Lin listed as Executive Vice President, Elanco USA, Corporate Strategy and Global Marketing (previously Executive Vice President, Elanco USA and Global Strategy) in SEC filings |
| Mar 5, 2019 | Ramiro Martin Cabral listed as Executive Vice Presideent, Elanco International (previously Executive Vice President, Elanco International and Global Customer Value) in SEC filings |
| Mar 5, 2019 | Jeffrey N Simmons listed as Presiident, CEO & Director (previously President, CEO and Director) in SEC filings |
| Mar 5, 2019 | David S Kinard listed as Executive Vice President, Human Resources (previously Executive Vice President, Human Resources and Corporate Affairs) in SEC filings |
| Dec 6, 2018 | Todd S. Young listed as Executive Vice President and Chief Financial Officer (previously Exec VP & CFO) in SEC filings |
| Nov 1, 2018 | Todd S. Young became Exec VP & CFO |
| Sep 26, 2018 | Michael-Bryant Hicks listed as Executive Vice President, General Counsel and Corporate Secretary (previously Officer Title: Executive Vice President, General Counsel and Corporate Secretary) in SEC filings |
| Sep 24, 2018 | James M Meer became Chief Accounting Officer |
| Sep 19, 2018 | Sarena S Lin became Executive Vice President, Elanco USA and Global Strategy |
| Sep 19, 2018 | Ramiro Martin Cabral became Executive Vice President, Elanco International and Global Customer Value |
| Sep 19, 2018 | R David Hoover became a director |
| Sep 19, 2018 | Michael-Bryant Hicks became Officer Title: Executive Vice President, General Counsel and Corporate Secretary |
| Sep 19, 2018 | Michael J Harrington became a director |
| Sep 19, 2018 | Lucas Montarce became Acting Chief Financial Officer |
| Sep 19, 2018 | Lawrence Erik Kurzius became a director |
| Sep 19, 2018 | LILLY ELI & CO became a 10% owner |
| Sep 19, 2018 | Kapila K Anand became a director |
| Sep 19, 2018 | Joshua L Smiley became a director |
| Sep 19, 2018 | Jeffrey N Simmons became a director |
| Sep 19, 2018 | Jeffrey N Simmons became President, CEO and Director |
| Sep 19, 2018 | David S Kinard became Executive Vice President, Human Resources and Corporate Affairs |
| Sep 19, 2018 | David Alan Urbanek became Executive Vice President, Manufacturing and Quality |
| Sep 19, 2018 | David A Ricks became a director |
| Sep 19, 2018 | Carl L McMillian became a director |
| Sep 19, 2018 | Aarti S. Shah became a director |
| Sep 19, 2018 | Aaron L Schacht became Executive Vice President, Innovation, Regulatory and Business Development |
Not reported recently (21)
- Todd S. Young · Last reported as Executive Vice President and Chief Financial Officer in an SEC filing dated Mar 5, 2025
- John P Bilbrey · Last reported as a director in an SEC filing dated Dec 3, 2024
- William F Doyle · Last reported as a director in an SEC filing dated Dec 3, 2024
- Craig S. Wallace · Last reported as a director in an SEC filing dated Dec 3, 2024
- Kathy V Turner · Last reported as a director in an SEC filing dated Dec 3, 2024
- Marcela A. Kirberger · Last reported as Executive Vice President, General Counsel and Corporate Secretary in an SEC filing dated Jul 5, 2023
- David Alan Urbanek · Last reported as Executive Vice President, Manufacturing and Quality in an SEC filing dated Mar 6, 2023
- Scott D. Ferguson · Last reported as a director in an SEC filing dated May 18, 2022
- Dirk Ehle · Last reported as Ex VP & Pres Elanco Europe in an SEC filing dated Dec 2, 2021
- Joyce J. Lee · Last reported as Ex VP Prs US Pet Hlth Com Op in an SEC filing dated Dec 2, 2021
- Sachem Head GP LLC · Last reported as a director in an SEC filing dated Dec 2, 2021
- Sachem Head Capital Management LP · Last reported as a director in an SEC filing dated Dec 2, 2021
- Uncas GP LLC · Last reported as a director in an SEC filing dated Dec 2, 2021
- Racquel Harris Mason · Last reported as Executive Vice President and Chief Marketing Officer in an SEC filing dated Jul 2, 2021
- Michael-Bryant Hicks · Last reported as Executive Vice President, General Counsel and Corporate Secretary in an SEC filing dated Mar 3, 2021
- Sarena S Lin · Last reported as Executive Vice President, Elanco USA, Corporate Strategy and Global Marketing in an SEC filing dated Mar 3, 2020
- David A Ricks · Last reported as a director in an SEC filing dated Sep 19, 2018
- Lucas Montarce · Last reported as Acting Chief Financial Officer in an SEC filing dated Sep 19, 2018
- Joshua L Smiley · Last reported as a director in an SEC filing dated Sep 19, 2018
- Aarti S. Shah · Last reported as a director in an SEC filing dated Sep 19, 2018
- Carl L McMillian · Last reported as a director in an SEC filing dated Sep 19, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ELAN Proposed Insider Sales (Form 144)
Latest: 2026-10-15
? Form 144 Guide
Last 30d:
1 filing
· $100K notice value
· Last 90d:
1 filing
· $100K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Bettington Timothy J (1, $100K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 | Bettington Timothy J | Officer | 4,350 | $100.0K | 2026-10-15 | UBS Financial Services Inc. | 10b5-1 | EDGAR |
| 2025-08-11 | Todd S and Jennifer G Young Living Trust Dtd 08/03/2021 | Former CFO | 49,333 | $830.0K | 2025-08-11 | UBS Financial Services Inc | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-06
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-06 | Earnings results | EDGAR |
| 2026-08-05 | Earnings results | EDGAR |
| 2026-05-27 | Shareholder vote results | EDGAR |
| 2026-05-06 | Earnings results | EDGAR |
| 2026-02-24 | Earnings results | EDGAR |
| 2026-01-12 | Regulation FD disclosure | EDGAR |
| 2025-12-09 | Restructuring costs · Regulation FD disclosure | EDGAR |
| 2025-11-05 | Earnings results | EDGAR |
| 2025-11-03 | Material agreement · New debt obligation | EDGAR |
| 2025-08-07 | Earnings results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-24 | 0001739104-26-000012 | EDGAR |
| 2025-02-25 | 0001739104-25-000014 | EDGAR |
| 2024-02-26 | 0001739104-24-000009 | EDGAR |
| 2023-03-01 | 0001739104-23-000004 | EDGAR |
| 2022-02-28 | 0001739104-22-000005 | EDGAR |
| 2021-03-01 | 0001739104-21-000004 | EDGAR |
| 2020-02-28 | 0001739104-20-000005 | EDGAR |
| 2019-02-20 | 0001739104-19-000006 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-11-06 | 0001739104-26-000057 | EDGAR |
| 2026-08-05 | 0001739104-26-000043 | EDGAR |
| 2026-05-06 | 0001739104-26-000030 | EDGAR |
| 2025-11-05 | 0001739104-25-000071 | EDGAR |
| 2025-08-07 | 0001739104-25-000055 | EDGAR |
| 2025-05-07 | 0001739104-25-000042 | EDGAR |
| 2024-11-07 | 0001739104-24-000039 | EDGAR |
| 2024-08-08 | 0001739104-24-000027 | EDGAR |
| 2024-05-08 | 0001739104-24-000018 | EDGAR |
| 2023-11-07 | 0001739104-23-000023 | EDGAR |
ETF Holders
146 ETFs hold ELAN
25 shown · $2.49B total exposure · 0.21% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.38% | $465.4M | $121.4B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $356.4M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.14% | $251.8M | — | 2026-09-30 |
| 4 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.79% | $214.1M | — | 2026-11-05 |
| 5 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.25% | $163.9M | — | 2026-09-30 |
| 6 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.44% | $136.9M | — | 2026-11-05 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.14% | $126.0M | — | 2026-09-30 |
| 8 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.35% | $90.3M | $25.6B | 2026-11-05 |
| 9 | XMMO Invesco S&P MidCap Momentum ETF | Invesco | 1.46% | $88.0M | — | 2026-11-05 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.24% | $82.0M | — | 2026-11-05 |
| 11 | IJK iShares S&P Mid-Cap 400 Growth ETF | iShares (BlackRock) | 0.77% | $78.4M | $10.2B | 2026-11-06 |
| 12 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.35% | $64.9M | $18.3B | 2026-11-05 |
| 13 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.10% | $54.3M | $56.9B | 2026-11-06 |
| 14 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.06% | $47.1M | — | 2026-11-05 |
| 15 | IHE iShares U.S. Pharmaceuticals ETF | iShares (BlackRock) | 2.72% | $43.7M | $1.7B | 2026-11-06 |
| 16 | VHT Vanguard Health Care ETF | Vanguard | 0.16% | $34.2M | — | 2026-09-30 |
| 17 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.22% | $33.0M | — | 2026-08-31 |
| 18 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.03% | $27.9M | $82.9B | 2026-11-06 |
| 19 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.28% | $24.0M | $8.6B | 2026-11-05 |
| 20 | MOO VanEck Agribusiness ETF | VanEck | 1.82% | $20.1M | $1.1B | 2026-11-05 |
| 21 | MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF | SPDR (State Street) | 0.72% | $19.5M | $2.7B | 2026-11-05 |
| 22 | IVOO Vanguard S&P Mid-Cap 400 ETF | Vanguard | 0.33% | $18.7M | — | 2026-09-30 |
| 23 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.12% | $18.2M | $14.8B | 2026-11-06 |
| 24 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.02% | $17.1M | $93.2B | 2026-11-06 |
| 25 | CGMM Capital Group U.S. Small and Mid Cap ETF | Capitalgroup | 0.43% | $15.3M | $3.5B | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.41
TTM Revenue
$5.02B
TTM Net Income
$-199.00M
TTM Op. Cash Flow
$617.00M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $1.37B | $54.00M | $0.11 | $277.00M |
| Q1 '26 | 2026-03-31 | $1.37B | $57.00M | $0.11 | $13.00M |
| Q4 '25 | 2025-12-31 | $1.14B | $-276.00M | $-0.56 | $108.00M |
| Q3 '25 | 2025-09-30 | $1.14B | $-34.00M | $-0.07 | $219.00M |
| Q2 '25 | 2025-06-30 | $1.24B | $11.00M | $0.02 | $237.00M |
| Q1 '25 | 2025-03-31 | $1.19B | $67.00M | $0.13 | $-4.00M |
| Q4 '24 | 2024-12-31 | $1.02B | $-8.00M | $-0.02 | $177.00M |
| Q3 '24 | 2024-09-30 | $1.03B | $364.00M | $0.73 | $162.00M |
| Q2 '24 | 2024-06-30 | $1.18B | $-50.00M | $-0.10 | $200.00M |
| Q1 '24 | 2024-03-31 | $1.21B | $32.00M | $0.06 | $2.00M |
| Q4 '23 | 2023-12-31 | $1.03B | $-141.00M | $-0.29 | $157.00M |
| Q3 '23 | 2023-09-30 | $1.07B | $-1.10B | $-2.22 | $198.00M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.06
P/S
2.70
EV/EBITDA
16.50
EV/Sales
3.36
ROE
-3.0%
ROA
-1.5%
Div Yield
0.00%
FCF Yield
4.55%
Debt/Equity
0.58
Current Ratio
—
Market Cap
$13.56B
as of 2026-11-09
ELAN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 45.9 | +45.5% | +31.0% | 27 |
| JNJ Johnson & Johnson | $664.9B | 42.8 | +7.8% | +36.0% | 58 |
| MRK Merck & Co., Inc. | $361.7B | 153.1 | +4.9% | +39.5% | 46 |
| PFE Pfizer Inc. | $167.5B | 42.1 | +1.3% | +17.2% | 58 |
| BMY Bristol-Myers Squibb Co. | $127.0B | 13.8 | +3.1% | +17.0% | 38 |
| ZTS ZOETIS INC. | $32.3B | 13.6 | +2.6% | −34.7% | 10 |
| VTRS Viatris Inc. Common Stock | $22.8B | — | +4.3% | +64.3% | 42 |
| JAZZ Jazz Pharmaceuticals, Inc. | $15.1B | 78.1 | +13.5% | +40.3% | 11 |
| ELAN Elanco Animal Health Incorporated Common | $12.9B | — | +12.0% | +20.1% | 0 |
| Peer median | $147.3B | 42.8 | +4.6% | +33.5% | 40 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
31.11M
SI % of Float
6.29%
Days to Cover
6.39
Short Vol Ratio
53.5%
Free Float
494.41M
Float %
99.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-05-15